BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 132 filers reported holding BRIDGEBIO PHARMA INC in Q3 2020. The put-call ratio across all filers is 0.69 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $1,883,000 | +62.5% | 185,533 | +167.0% | 0.00% | 0.0% |
Q4 2021 | $1,159,000 | -59.9% | 69,476 | +12.7% | 0.00% | -50.0% |
Q3 2021 | $2,890,000 | -17.3% | 61,664 | +7.6% | 0.00% | 0.0% |
Q2 2021 | $3,493,000 | +7.3% | 57,297 | +8.4% | 0.00% | 0.0% |
Q1 2021 | $3,256,000 | +38.0% | 52,854 | +59.4% | 0.00% | +100.0% |
Q4 2020 | $2,359,000 | +114.1% | 33,167 | +12.9% | 0.00% | 0.0% |
Q3 2020 | $1,102,000 | +12.6% | 29,366 | -2.2% | 0.00% | 0.0% |
Q2 2020 | $979,000 | +106.1% | 30,033 | +83.3% | 0.00% | – |
Q1 2020 | $475,000 | -29.1% | 16,382 | -14.3% | 0.00% | – |
Q4 2019 | $670,000 | +74.0% | 19,123 | +6.7% | 0.00% | – |
Q3 2019 | $385,000 | – | 17,929 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |